3/20/2013

Biogen Idec obtained a new patent for its multiple sclerosis drug Tecfidera, which could receive FDA approval this month. The patent on a daily dosing regimen of 480 milligrams is due to expire in 2028.

Full Story:
Reuters

Related Summaries